Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Endoprosthesis Provides Superior Patency Versus Balloon Angioplasty for Challenging Cases

June 28, 2016 By W. L. Gore & Associates

W. L. Gore & Associates, Inc. announced the publication of clinical study results in the Journal of Vascular Surgery detailing the success of the GORE VIABAHN Endoprosthesis with heparin bioactive surface in arteriovenous (AV) access graft outflow interventions.

Overall, the device performed significantly better compared to percutaneous transluminal angioplasty (PTA) alone for treatment of challenging AV access cases in a real-world patient population, both in terms of primary patency and in number of interventions over the study period.

Notably, the Gore REVISE Clinical Study was the first AV access stent-graft study to include patients with thrombosed grafts and placement of the device across the elbow joint.

The GORE VIABAHN Endoprosthesis (Credit: Business Wire)

Key findings from the study:

  • The device delivered a 47 percent improvement in target lesion primary patency and a 48 percent improvement in circuit primary patency over PTA alone at six months
  • The device demonstrated a 50 percent increase over PTA in target lesion primary patency at six months when treating thrombosed AV access circuits
  • When placed across the elbow, the VIABAHN endoprosthesis delivered 72 percent target lesion primary patency at six months and 83 percent access secondary patency at 24 months (n=22)
  • Median time to target lesion reintervention or graft abandonment with the endoprosthesis was approximately twice that achieved with PTA (203 versus 108 days).
  • Placement of VIABAHN led to 27 percent fewer interventions both at the target lesion and in the dialysis access circuit over a 24-month period compared to PTA

According to the United States Renal Data System, there are over 700,000 patients with end-stage renal disease and nearly 90 percent of those patients are receiving hemodialysis. Arteriovenous grafts (AVG) are often used to create dialysis circuits for patients.

Failing dialysis circuits often result in the placement of infection-prone central venous catheters while a new dialysis access circuit is surgically created and matured. Balloon angioplasty is a common fix in the event of a failing circuit, but many patients are unresponsive to the procedure, which has left a gap in treatment capabilities for difficult anatomies.

The clinical study demonstrated that placement of a stent-graft leads to better patient outcomes with reduced interventions, a positive finding for all stakeholders involved in the patient’s care.

In 2013, the Food and Drug Administration granted indication for the GORE VIABAHN Endoprosthesis to maintain and salvage failing dialysis access circuits.

The device is a low profile, flexible, self-expanding, and small-diameter endoprosthesis and the only stent or stent-graft to receive approval for the superficial femoral artery (SFA), in-stent restenosis of bare-metal stents in the SFA, iliac artery, and AV access, according to Gore.

It is constructed with a reinforced, biocompatible, expanded polytetrafluorethylene liner and attached to an external nitinol stent structure. The endoprosthesis also features the company’s CBAS heparin surface, a bonding technology designed to resist thrombus formation.

Related Articles Read More >

This is a Boston Scientific illustration of its Eluvia drug-eluting stent for treating peripheral artery disease or PAD.
How Boston Scientific is advancing its PAD-treating drug-eluting stent
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
The top nitinol cardiac medtech news of 2025 (so far)
Camgenium and Cardiac Tech partner on Pace-Protect safety device
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
Q&A with Darshin Patel, who led the Edwards Lifesciences Sapien M3 TMVR system’s development
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe